SIRT2 and breast carcinoma: The combination of MYC inhibitor, dinaciclib, and PARP inhibitor, niraparib, induced a potent synthetic lethal effect on TNBC cells with MYC overexpression.429 Sirtuin2 (SIRT2) is a kind of epigenetic regulator, and its disorder is the main factor in inducing cancer.430 SIRT2 inhibitor and sorafenib combination treatment exhibited potent ability to induce MCF-7 cell apoptosis, as well potential synthetic lethality effect.431 Aurora-A overexpression has been observed in breast cancer and is associated with poor prognosis.